Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.
about
Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitorsA reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studiesPatterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab
P2860
Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Change in Neutrophil-to-lympho ...... tastatic renal cell carcinoma.
@en
Change in Neutrophil-to-lymphocyte ratio
@nl
type
label
Change in Neutrophil-to-lympho ...... tastatic renal cell carcinoma.
@en
Change in Neutrophil-to-lymphocyte ratio
@nl
prefLabel
Change in Neutrophil-to-lympho ...... tastatic renal cell carcinoma.
@en
Change in Neutrophil-to-lymphocyte ratio
@nl
P2093
P2860
P1476
Change in Neutrophil-to-lympho ...... etastatic renal cell carcinoma
@en
P2093
Audrey Duquette
Bradley A McGregor
Chad J Creighton
Craig K Norton
Dylan J Martini
Eliezer M Van Allen
Joaquim Bellmunt
John A Steinharter
Katherine M Krajewski
Lauren C Harshman
P2860
P2888
P356
10.1186/S40425-018-0315-0
P577
2018-01-22T00:00:00Z
P6179
1100433880